Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

被引：175

作者：

Mellinghoff, Sibylle C. ^{[1
,2
]}

Panse, Jens ^{[3
]}

Alakel, Nael ^{[4
]}

Behre, Gerhard ^{[5
]}

Buchheidt, Dieter ^{[6
]}

Christopeit, Maximilian ^{[7
]}

Hasenkamp, Justin ^{[8
]}

Kiehl, Michael ^{[9
]}

Koldehoff, Michael ^{[10
]}

Krause, Stefan W. ^{[11
]}

Lehners, Nicola ^{[12
]}

von Lilienfeld-Toal, Marie ^{[13
]}

Loehnert, Annika Y. ^{[2
]}

Maschmeyer, Georg ^{[14
]}

Teschner, Daniel ^{[15
]}

Ullmann, Andrew J. ^{[16
]}

Penack, Olaf ^{[17
]}

Ruhnke, Markus ^{[18
]}

Mayer, Karin ^{[19
]}

Ostermann, Helmut ^{[20
]}

Wolf, Hans-H. ^{[21
]}

Cornely, Oliver A. ^{[1
,2
,22
]}

机构：

[1] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, German Ctr Infect Res DZIF, Cologne, Germany

[3] Univ Hosp RWTH Aachen, Dept Oncol Haematol Haemostaseol & Stem Cell Tran, Aachen, Germany

[4] Univ Hosp Dresden, Dept Internal Med Haematol & Oncol 1, Dresden, Germany

[5] Leipzig Univ Hosp, Div Haematol & Oncol, Leipzig, Germany

[6] Heidelberg Univ, Mannheim Univ Hosp, Dept Internal Med Haematol & Oncol, Mannheim, Germany

[7] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

[8] Univ Med Gottingen, Clin Haematol & Med Oncol, Dept Stem Cell Transplantat, Gottingen, Germany

[9] Klinikum Frankfurt Oder, Dept Internal Med 1, Frankfurt, Oder, Germany

[10] Univ Duisburg Essen, Univ Hosp Essen, Dept Bone Marrow Transplantat, West German Canc Ctr, Duisburg, Germany

[11] Univ Hosp Erlangen, Dept Internal Med 5, Erlangen, Germany

[12] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

[13] Univ Hosp Jena, Dept Haematol & Oncol, Jena, Germany

[14] Klinikum Ernst von Bergmann, Dept Haematol Oncol & Palliat Care, Potsdam, Germany

[15] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Haematol Med Oncol & Pneumol, Mainz, Germany

[16] Univ Hosp Wuerzburg, Dept Internal Med 2, Wurzburg, Germany

[17] Charite, Dept Haematol Oncol & Tumour Immunol, Berlin, Germany

[18] Paracelsus Kliniken Osnabruck, Dept Haematol & Oncol, Osnabruck, Germany

[19] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany

[20] Univ Munich, Dept Haematol & Oncol, Munich, Germany

[21] Univ Hosp Halle, Dept Internal Med 4, Halle, Germany

[22] Univ Cologne, Clin Trials Ctr Cologne ZKS Koln, Cologne, Germany

来源：

ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 02期

关键词：

Invasive fungal infection; Antifungal prophylaxis; Itraconazole; Fluconazole; Posaconazole; Amphotericin B; Liposomal; Isavuconazole; LIPOSOMAL AMPHOTERICIN-B; HIGH-RISK PATIENTS; ANTIFUNGAL PROPHYLAXIS; ADVERSE EVENTS; SINGLE-CENTER; INDUCTION CHEMOTHERAPY; EUROPEAN CONFEDERATION; CHANGING EPIDEMIOLOGY; ASPERGILLUS-FUMIGATUS; POSACONAZOLE TABLET;

D O I：

10.1007/s00277-017-3196-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption.

引用

页码：197 / 207

页数：11

共 114 条

[11] Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains [J].

Castanheira, Mariana ;

Woosley, Leah N. ;

Diekema, Daniel J. ;

Messer, Shawn A. ;

Jones, Ronald N. ;

Pfaller, Michael A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2655-2659

[12] Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014 [J].

Chau, M. M. ;

Kong, D. C. M. ;

van Hal, S. J. ;

Urbancic, K. ;

Trubiano, J. A. ;

Cassumbhoy, M. ;

Wilkes, J. ;

Cooper, C. M. ;

Roberts, J. A. ;

Marriott, D. J. E. ;

Worth, L. J. .

INTERNAL MEDICINE JOURNAL, 2014, 44 (12B) :1364-1388

[13] Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life [J].

Chong, Ga-Lai M. ;

Broekman, Fleur ;

Polinder, Suzanne ;

Doorduijn, Jeanette K. ;

Lugtenburg, Pieternella J. ;

Verbon, Annelies ;

Cornelissen, Jan J. ;

Rijnders, Bart J. A. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (01) :82-87

[14] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[15] ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013 [J].

Cornely, O. A. ;

Arikan-Akdagli, S. ;

Dannaoui, E. ;

Groll, A. H. ;

Lagrou, K. ;

Chakrabarti, A. ;

Lanternier, F. ;

Pagano, L. ;

Skiada, A. ;

Akova, M. ;

Arendrup, M. C. ;

Boekhout, T. ;

Chowdhary, A. ;

Cuenca-Estrella, M. ;

Freiberger, T. ;

Guinea, J. ;

Guarro, J. ;

de Hoog, S. ;

Hope, W. ;

Johnson, E. ;

Kathuria, S. ;

Lackner, M. ;

Lass-Floerl, C. ;

Lortholary, O. ;

Meis, J. F. ;

Meletiadis, J. ;

Munoz, P. ;

Richardson, M. ;

Roilides, E. ;

Tortorano, A. M. ;

Ullmann, A. J. ;

van Diepeningen, A. ;

Verweij, P. ;

Petrikkos, G. .

CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 :5-26

[16] European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases [J].

Cornely, O. A. ;

Cuenca-Estrella, M. ;

Meis, J. F. ;

Ullmann, A. J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 :1-4

[17] Lack of Evidence for Exposure-Response Relationship in the Use of Posaconazole as Prophylaxis Against Invasive Fungal Infections [J].

Cornely, O. A. ;

Ullmann, A. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) :351-352

[18] Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Bresnik, Mark ;

Ebrahimi, Ramin ;

Ullmann, Andrew J. ;

Bouza, Emilio ;

Heussel, Claus Peter ;

Lortholary, Olivier ;

Rieger, Christina ;

Boehme, Angelika ;

Aoun, Mickael ;

Horst, Heinz-August ;

Thiebaut, Anne ;

Ruhnke, Markus ;

Reichert, Dietmar ;

Vianelli, Nicola ;

Krause, Stefan W. ;

Olavarria, Eduardo ;

Herbrecht, Raoul .

CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) :1289-1297

[19] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[20] Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia [J].

Cornely, Oliver A. ;

Leguay, Thibaut ;

Maertens, Johan ;

Vehreschild, Maria J. G. T. ;

Anagnostopoulos, Achilles ;

Castagnola, Carlo ;

Verga, Luisa ;

Rieger, Christina ;

Kondakci, Mustafa ;

Haerter, Georg ;

Duarte, Rafael F. ;

Allione, Bernardino ;

Cordonnier, Catherine ;

Heussel, Claus Peter ;

Morrissey, C. Orla ;

Agrawal, Samir G. ;

Donnelly, J. Peter ;

Bresnik, Mark ;

Hawkins, Michael J. ;

Garner, Will ;

Goekbuget, Nicola .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (08) :2359-2367

← 1 2 3 4 5 6 7 8 9 10 →